Hemispherx Biopharma Announces Fiscal 2011 Year Results
14. März 2012 15:02 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the fiscal year ended December 31, 2011. The net loss for 2011's twelve month...
Hemispherx Biopharma Gains Regulatory Approval in Latin America
26. Januar 2012 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos,...
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
17. Januar 2012 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today the granting of two new United States Patents for the use of...
FDA Grants Hemispherx Biopharma Extension in Its Pending New Drug Application (NDA) for the Treatment of Chronic Fatigue Syndrome (CFS)
11. Januar 2012 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration ("FDA") granted an...
Hemispherx Biopharma's 2011 Stockholder Annual Meeting Final Results
08. Dezember 2011 16:15 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 8, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") has concluded its 2011 Stockholder Annual Meeting with the passage of Proposal No. 4 to...
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
09. November 2011 16:13 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today that the Company will extend the time allowed for stockholders to vote on proposal number 4...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
09. November 2011 12:26 ET
|
Hemispherx Biopharma, Inc.
Operating Expenses Continue to be Reduced
Construction at New Jersey Facility Underway
New Clinical Trial Initiated
PHILADELPHIA, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc....
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
24. Oktober 2011 10:22 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 24, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, October 27, 2011 at 2:00...
Hemispherx Biopharma Reports on Annual Stockholder Meeting
17. Oktober 2011 11:45 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced that it held its 2011 Annual Meeting of Stockholders on October 13, 2011. Final voting results will be...
2011 Nobel Prize Awarded for Discovery of Innate Immunity Pathways -- Research Included Studies on Experimental Drug in Hemispherx Biopharma Portfolio
11. Oktober 2011 10:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 11, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) ("Hemispherx" or the "Company") offered congratulations and homage to Ralph M. Steinman (1943-2011) who...